• 1
    Porter J., Canaday WR Jr. Hematologic values in Mongrel and Greyhound dogs being screened for research use. J Am Vet Med Assoc 1971;159: 16031606.
  • 2
    Sullivan PS, Evans HL, McDonald TP. Platelet concentration and hemoglobin function in Greyhounds. J Am Vet Med Assoc 1994;205: 838841.
  • 3
    Steiss JE, Brewer WG, Welles E., Wright JC. Hematologic and serum biochemical reference values in retired Greyhounds. Compend Cont Educ 2000;22: 243248.
  • 4
    Feeman W., Couto CG, Gray TL. Serum creatinine concentrations in retired racing Greyhounds. Vet Clin Pathol 2003;32: 4042.
  • 5
    Fayos M., Couto CG, Iazbik MC, Wellman ML. Serum protein electrophoresis in retired racing Greyhounds. Vet Clin Pathol 2005;43: 397400.
  • 6
  • 7
    Stokol T., Parry BW. Canine von Willebrand disease: A review. Aust Vet Pract 1993;23: 94103.
  • 8
    Brooks M.. A review of canine inherited bleeding disorders: Biochemical and molecular strategies for disease characterization and carrier detection. J Hered 1999;20: 112118.
  • 9
    Sato I., Anderson GA, Parry BW. An interobserver and intraobserver study of buccal mucosal bleeding time in Greyhounds. Res Vet Sci 2000;68: 4145.
  • 10
    Ingerman-Wojensky CM. Simultaneous measurement of platelet aggregation and the release reaction in platelet-rich plasma and in whole blood. J Med Tech. 1984;1: 697701.
  • 11
    Abbate R., Favilla S., Boddi M., Constanzo G., Prisco D.. Factors influencing platelet aggregation in whole blood. Am J Clin Pathol 1986;85: 9196.
  • 12
    Michelson AD. Flow cytometry: a clinical test of platelet function. Blood 1996;87: 49254936.
  • 13
    Dean JA, Blanchette VS, Carcao MD, et al. Von Willebrand disease in a pediatric-based population-comparison of type 1 diagnostic criteria and use of the PFA-100± and a von Willebrand factor/collagen binding assay. Thromb Haemost 2000;84: 401409.
  • 14
    Keidel A., Mischke R.. Clinical evaluation of platelet function analyzer PFA-100± in dogs. Berl Munch Tierarztl Wochenschr 1998;111: 452456.
  • 15
    Callan MB, Giger U.. Assessment of a point-of-care instrument for identification of primary hemostatic disorders in dogs. Am J Vet Res 2001;62: 652658.
  • 16
    Mischke R., Keidel A.. Influence of platelet count, acetylsalicylic acid, von Willebrand's disease, coagulopathies, and haematocrit on results obtained using a platelet function analyser in dogs. Vet J 2003;165: 4352.
  • 17
    Callan MB, Giger U.. Effect of desmopressin acetate administration on primary hemostasis in Doberman Pinschers with type-1 von Willebrand disease as assessed by a point-of-care instrument. Am J Vet Res 2002;63: 17001706.
  • 18
    Kundu SK, Heilmann EJ, Sio R., et al. Description of an in vitro platelet function analyzer: PFA-100®. Semin Thromb Haemost 1995;21(Suppl 2):106112.
  • 19
    Sadler Je, Matsushita T., Dong Z., et al. Molecular mechanism and classification of von Willebrand disease. Thromb Haemost 1995;74: 161166.
  • 20
    Tarnow I., Kristensen AT, Olsen LH, Pedersen HD. Assessment of changes in hemostatic markers in Cavalier King Charles Spaniels with myxomatous mitral valve disease. Am J Vet Res 2004;12: 16441652.
  • 21
    Mammen EF, Comp PC, Gosselin R., et al. PFA-100® system: a new method for assesment of platelet dysfunction. Semin Thromb Hemost 1998;24: 195202.
  • 22
    Johnstone IB. Plasma von Willebrand factor-collagen binding activity in normal dogs and in dogs with von Willebrand's disease. J Vet Diagn Invest 1999;11: 308313.
  • 23
    Siekmann J., Turecek PL, Fischer BE, et al. Characterization of plasma derived and recombinant human vWF by improved collagen binding assays. Thromb Haemost 1995;73: 11601166.
  • 24
    Favaloro EJ. Von Willebrand factor collagen-binding (activity) assay in the diagnosis of von Willebrand disease: A 15-year journey. Semin Thromb Hemost 2002;28: 191202.
  • 25
    Benson RE, Catalfamo JL, Brooks M., Dodds WJ. A sensitive immunoassay for von Willebrand factor. J Immunoassay 1991;12: 371390.
  • 26
    Lara A., Rodríguez E., Espinosa de los Monteros A., et al. Increased platelet function in dogs with malignant solid tumors determined with PFA-100®. Veterinary Cancer Society 23rd Annual Conference, Madison, WI, September 2003.
  • 27
    Anand A., Feffer SE. Hematocrit and bleeding time: An update. South Med J 1994;87: 299301.
  • 28
    Fernandez F., Goudable C., Sie P., et al. Low hematocrit and prolonged bleeding time in uremic patients: Effect of red cell transfusions. Br J Haematol 1985;59: 139148.
  • 29
    Escolar G., Cases A., Vinas M., et al. Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100): Influence of hematocrit elevation. Haematologica 1999;84: 614619.
  • 30
    Bodey AR, Rampling MW. A comparative study of the haemorreology of various breeds of dog. Clinical Haemorreol Microcircul 1998;18: 291298.
  • 31
    Pape LA, Rippe JM, Walker WS, et al. Effect of the cessation of training on left ventricular function in racing Greyhounds. Serial studies in a model of cardiac hypertrophy. Basic Res Cardiol 1984;79: 98109.
  • 32
    Pape LA, Price JM, Alpert JS, Rippe JM. Hemodynamics and left ventricular function: a comparison between adult racing Greyhounds and Greyhounds completely untrained from birth. Basic Res Cardiol 1986;81: 417424.
  • 33
    Clemmons RM, Meyer KM. Acquisition and aggregation of canine blood platelets: Basic mechanisms of function and differences because of breed origin. Am J Vet Res 1984;45: 137144.
  • 34
    Feingold HM, Pracek LE, Melaragno AJ. Coagulation assays and platelet aggregation patterns in human, baboon, and canine blood. Am J Vet Res 1986;47: 21972199.
  • 35
    Cattaneo M., Federici AB, Lecchi A., et al. Evaluation of the PFA 100® system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Thromb Haemost 1999;82: 3539.